Participants assigned to this arm will receive intravenous (IV) iron sucrose (Blogen) utilizing a step-up safety protocol to minimize acute hypersensitivity risks. On Day 1 (Baseline), participants will receive an initial safety and tolerability dose of 100 mg of iron sucrose diluted in 100 mL of 0.9% Normal Saline (NS), infused intravenously over a minimum of 15 minutes. Participants will be monitored for at least 30 minutes post-infusion for acute adverse events or hypersensitivity reactions. In the absence of any safety signals or severe drug intolerance, subsequent maintenance doses will scale to 200 mg of iron sucrose diluted in 100 mL of 0.9% NS, administered via intravenous infusion over 30 minutes. This 200 mg dose will be administered twice weekly, with a strict minimum of 48 hours between consecutive administrations, to reach a total weekly dose of 400 mg, until the participant's predefined cumulative iron deficit target is achieved.

Participants assigned to this arm will receive intravenous (IV) iron sucrose (Blogen, 20 mg/mL concentration) utilizing a step-up safety sequence delivered via manual gravity drip. On Day 1 (Baseline), participants will receive an initial safety and tolerability check dose of 100 mg (5 mL) of iron sucrose diluted in 100 mL of sterile 0.9% Normal Saline (NS) and infused over a minimum of 15 minutes. Following a clinical evaluation to confirm the absence of acute hypersensitivity or infusion reactions, subsequent maintenance doses will escalate to 200 mg (10 mL) of iron sucrose. Each 200 mg maintenance dose will be diluted in 150 mL of sterile 0.9% NS, yielding a 160 mL total fluid volume with a stable iron concentration of 1.25 mg/mL (safely above the manufacturer's 1 mg/mL stability floor). The solution will be administered via an intravenous gravity drip set, with the flow rate manually calibrated and monitored by clinical staff to ensure the full volume is infused over exactly 30 mi